Table 2.

Assay of anti-MART-1 reactivity in peripheral blood mononuclear cells (PBMCs) from patients immunized with recombinant adenovirus encoding MART-1

		Before immunization*			After immunization*,†
Patient No.	T2	T2 (flu)	T2 (MART)	T2	T2 (flu)	T2 (MART)
2	0	21	6	39	34	10
3	142	126	121	23	63	0
4	ND	ND	ND	0	21	4432
5	195	207	190	335	331	981
6	37	37	682	51	38	69
7	70	71	79	56	46	48
8	ND	ND	ND	114	259	7058
9	0	0	893	0	0	2108
11	29	43	44	32	45	67
12	0	0	0	0	0	112
13	18	37	6027	0	0	2122
14	11	11	16	0	0	0
16	37	50	223	29	33	462
17	123	136	0	124	170	35
19	44	49	3483	15	19	2884
21	0	0	145	0	0	11232
22	0	0	5550	0	0	2485
24	ND	ND	ND	0	0	0
25	573	604	1900	0	0	1453
27	0	0	0	0	0	41
28	171	140	8832	447	330	13262
29	0	0	4701	0	0	4175
30	52	77	49	0	0	0
32	223	142	5527	34	7	7034
33	0	0	3696	0	0	516

^*Values = picograms interferon gamma per milliliter. Values greater than 100 pg interferon gamma and at least twice those of controls are underlined. All assays were conducted on cells 7 days after three in vitro stimulations (thus assayed on day 21 of culture) by incubating 10⁵ responders with 10⁵ T2 cells pulsed with MART-1 peptide (10 μg/mL) or flu peptide (1 μg/mL).

^†All postimmunization PBMCs were obtained after two injections of adenovirus MART-1 except for patients 4, 6, and 9 who were tested after three, one, and four immunizations, respectively, because of availability of PBMCs.